PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17-Reference-Cited by-同舟云学术

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

Published:2013-11-11 Issue:3 Volume:20 Page:744-753
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Karapetis Christos S.,Jonker Derek,Daneshmand Manijeh,Hanson Jennifer E.,O'Callaghan Christopher J.,Marginean Celia,Zalcberg John R.,Simes John,Moore Malcolm J.,Tebbutt Niall C.,Price Timothy J.,Shapiro Jeremy D.,Pavlakis Nick,Gibbs Peter,Van Hazel Guy A.,Lee Ursula,Haq Rashida,Virk Shakeel,Tu Dongsheng,Lorimer Ian A.J.,

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212);Clinical Cancer Research;2024-01-30

2. Colorectal Cancer and Role of Biomarkers in Diagnosis, Prognostification and Personalized Treatment;Molecular Biomarkers for Cancer Diagnosis and Therapy;2024

3. Gastrointestinal Malignancy: Genetic Implications to Clinical Applications;Cancer Treatment and Research;2024

4. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis;BMC Cancer;2023-11-16

5. Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer;Journal of Gastrointestinal Cancer;2023-08-23